Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From 1/10/19 lol
I ve been long gone lol
Uh oh.... and might be happening on that other Q stock soon...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148913151
ARLZQ: Bankruptcy PLAN effective. All shares cancelled.
https://otce.finra.org/otce/dailyList?viewType=Deletions
Constant dumping the last 2 days. Probably insiders unloading before the announcement that shareholders will not receive a settlement after all
ARLZQ...006...Gap filled today on the 100% move...http://schrts.co/cKdnfHuM...
ARLZQ...003...Item 2.01 Completion of Acquisition or Disposition of Assets.
On March 6, 2019, Old API Wind-down Ltd. (f/k/a Aralez Pharmaceuticals Inc.) (the “ Company ”) completed its previously announced sale of the Company’s TOPROL-XL® franchise to Toprol Acquisition LLC (“ Acquisition Sub ”), for approximately $130,000,000 as a credit bid (the “ Toprol Sale ”), pursuant to the Asset Purchase Agreement (the “ APA ”), dated September 18, 2018, by and among Acquisition Sub and Aralez Pharmaceuticals Trading DAC, a subsidiary of the Company. Acquisition Sub is owned by the secured lenders of the Company, Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P.
The foregoing description of the Toprol Sale does not purport to be complete and is qualified in its entirety by the APA, which is incorporated herein by reference to Exhibit 2.3 to the Company’s Form 8-K filed with the Securities and Exchange Commission on September 19, 2018.
https://www.otcmarkets.com/filing/html?id=13282997&guid=296tUK_WErCbYth
Just heard from legal reps. Their will be no distribution to shareholders and no reissue of stock to shareholders. Check with your tax person for loss declaration. I'm out @ 71,000 shares and in my opinion the way it unfolded was a tad dishonest.
ARLZQ...004...Nice move to .0115 followed by a dip to the .002 range which left an open gap in the .006 range that should fill...
Chart...http://schrts.co/eQegvnDT
https://www.otcmarkets.com/filing/html?id=13162447&guid=dBktUn0Vr9ul-th
Effective as of January 18, 2019, Sanjay Subramanian, 43, the Company’s current Treasurer, will assume the role of Chief Financial Officer. Prior to joining the company, Mr. Subramanian was the Director of Treasury at Bausch Health Companies. Mr. Subramanian started his finance career at General Motors Co. where he held various positions before leaving as the Treasurer of GM Korea.
Effective as of January 31, 2019, Christopher Freeland, 40, the Company’s current General Counsel, will also assume the role of Chief Operating Officer. Prior to being appointed as the Company’s General Counsel, Mr. Freeland was the Company’s Associate General Counsel. Prior to joining the Company, Mr. Freeland was an Associate General Counsel at American International Group. Mr. Freeland started his legal career as a corporate associate at Willkie Farr & Gallagher LLP.
Based on volume i d think bad?
Important Docket out yesterday "Notice of Hearing / Notice of Toprol Sale Hearing filed by Paul V. Shalhoub on behalf of Aralez Pharmaceuticals US Inc., et al.."
Remember that TOPROL valued $ 130 Millions.
https://cases.primeclerk.com/Aralez/Home-DocketInfo
11 Dockets out yesterday : https://cases.primeclerk.com/Aralez/Home-DocketInfo
$ARLZQ: NEWS... Intercept acquires Bezafibrate from Aralez-Pharma
Major HealthCare conference happening this week.....
37th Annual J.P. Morgan Healthcare Conference
https://globenewswire.com/news-release/2019/01/07/1681125/0/en/Intercept-Announces-NASH-and-PBC-Program-Updates.html
In addition, Intercept announced that it has acquired from Aralez Pharmaceuticals Inc. its license to develop and commercialize bezafibrate in the U.S., its IND on file with the FDA and other associated regulatory documentation, and a non-exclusive license to certain of Aralez’s intellectual property. Bezafibrate, a pan-peroxisome proliferator-activated receptor (PPAR) agonist that has been studied in PBC, is not approved in the U.S. for any indication. Intercept intends to initiate a Phase 2 study to evaluate the efficacy, safety and tolerability of bezafibrate in combination with OCA in patients with PBC, with the longer term goal to develop and seek regulatory approval for a fixed dose combination regimen in this indication and potentially other liver diseases.
“We are pleased to have acquired the U.S. rights to bezafibrate and look forward to studying it in combination with OCA as a potential treatment for progressive non-viral liver diseases. Based on the potential benefits of combining bezafibrate with OCA in PBC, we will initially study the combination in this indication,” said Christian Weyer, M.D., M.A.S., Intercept's Executive Vice President, Research & Development.
Go $ARLZQ
TOPROL-XL® Franchise transaction valued at U.S.$130 million will open soon more eyes :)
"The Company and certain of its affiliates continue to seek approval of the U.S. Bankruptcy Court for the sale of its TOPROL-XL® Franchise to its secured lender, certain funds managed by Deerfield Management Company, L.P. ("Deerfield"), in a transaction valued at U.S.$130 million "
Agree. Higher prices coming. Longs are holding.
$ARLZQ: Minimal selling.... Next Leg up coming
This is a very good base level here at $0.007
Massive break higher is on tap for Aralez.
GO $ARLZQ
Exact same trading patterns last 2 days. Drop thru the bid on low (under 100k) volume then slowly ramp up the bid (currently 0.0059). Just a patience play. Another extension on the docket gives them more time to play games, I guess. But you never know when they will pull the buy trigger.
$ARLZQ: I see $0.15/sh coming
But then again... thats just me :)
Currently at $0.0074
GO $ARLZQ
2 new filings in the docket for 01/03/2019
https://cases.primeclerk.com/Aralez/Home-DocketInfo
Docket# 419
Notice of Adjournment of Hearing / Notice of Cancellation of January 10, 2019 Omnibus Hearing filed by Paul V. Shalhoub on behalf of Aralez Pharmaceuticals US Inc., et al..
01/03/2019
Docket #418
Order, signed on 1/3/2019, Authorizing Continued Extension of Deadline to Comply with Section 345(b) of the Bankruptcy Code on an Interim Basis. (related document(s)395)
01/03/2019
ARLZQ possibly. 53% now after 430% yesterday
fairly low volume, next big Q bro?
- Armin
Amateur hour(s) over. Penny bid now. Nobody wanted to sell into their crappy lowball bids all day.
0087 X 0099 now. 5 mil still showing on the bid
About time but they still get no love so far. Let's see that 5 mil move up to 0.009 bid.
Stocktwits arlzchapter11 message board link
https://stocktwits.com/r/arlzchapter11/
162k volume all day so far. Huge bids have been stacked up 0.004, 0.005, 0.0055 and now 0.0057. They are getting no love.
Also notice the ask has been mysteriously thinning as well. 0.0086 had 50,000 taken out by just 1,100. 0.0088 ask just disappeared. This is so thin.
Bids stacked up all day barely any sales. Come in market makers, make a market !
What is the thought on commons here?
Bid creeping up 0.0055 now. Still not a seller in the house. Hit the ask champs!
Very active case Aralez Pharmaceuticals US Inc. (18-12425)
Yesterday January 02, 2019 got 2 dockets added
https://cases.primeclerk.com/Aralez/Home-DocketInfo
CDEL 300,000 @0.0052
ETRF 40,000 @0.0052
CSTI 100,000 @0.005
NITE 5,000,000 @0.004
None of them can get a fill.
5 Millions shares bidder @ 0.004 (NITE)
Hit 005 I bet you see him.
Prop bid as the 5 milly bidder is gone
Imo
Are commons done?
5M bid and he's not getting filled. Ask smacking to come shortly.